Journal of Biological Chemistry · 2002 · 1.8K citations · 50 references
Life SciencesBiochemistryImmunologyAntibody EngineeringCellular ImmunologyInnate ImmunityAntibody CharacterizationAntibody FunctionAntibody StructureGlycoengineering Of AntibodiesImmunoglobulin FunctionAntibody-dependent Cell-mediated CytotoxicityAntibody-dependent Cellular CytotoxicityCytotoxicity AssaysFc Neonatal Receptor BindingFc ReceptorsFc-mediated Effector Function EnhancementIgg-mediated CytotoxicityNeonatal Fc Receptor Binding
Lec13 cells, a variant Chinese hamster ovary cell line, were used to produce human IgG1 that were deficient in fucose attached to the Asn(297)-linked carbohydrate but were otherwise similar to that found in IgG1 produced in normal Chinese hamster ovary cell lines and from human serum. Lack of fucose on the IgG1 had no effect on binding to human FcgammaRI, C1q, or the neonatal Fc receptor. Although no change in affinity was found for the His(131) polymorphic form of human FcgammaRIIA, a slight improvement in binding was evident for FcgammaRIIB and the Arg(131) FcgammaRIIA polymorphic form. In contrast, binding of the fucose-deficient IgG1 to human FcgammaRIIIA was improved up to 50-fold. Antibody-dependent cellular cytotoxicity assays using purified peripheral blood monocytes or natural killer cells from several donors showed enhanced cytotoxicity, especially evident at lower antibody concentrations. When combined with an IgG1 Fc protein variant that exhibited enhanced antibody-dependent cellular cytotoxicity, the lack of fucose was synergistic.
50
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations
Medicine, Cancer Biology, Oncology +15
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Paul Carter, Leonard G. Presta, C Gorman et al. · Proceedings of the National Academy of Sciences · 1992 · 1.9K citations